Mavacamten : A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Hypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that Mavacamten can reduce Left Ventricular Outflow Tract (LVOT) involvement, cardiac hypercontraction, and hypertrophy. This review provides an overview of HCM, its pathophysiology, current treatments, synthesis of Mavacamten, and the clinical trials of Mavacamten.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Cardiovascular & hematological agents in medicinal chemistry - (2024) vom: 05. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdul Qadir Memon, Ayesha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Camzyos |
|---|
| Anmerkungen: |
Date Revised 08.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0118715257283752240325082733 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37073940X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37073940X | ||
| 003 | DE-627 | ||
| 005 | 20240408233425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240408s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0118715257283752240325082733 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM37073940X | ||
| 035 | |a (NLM)38584533 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abdul Qadir Memon, Ayesha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mavacamten |b A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Hypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that Mavacamten can reduce Left Ventricular Outflow Tract (LVOT) involvement, cardiac hypercontraction, and hypertrophy. This review provides an overview of HCM, its pathophysiology, current treatments, synthesis of Mavacamten, and the clinical trials of Mavacamten | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cardiac myosin inhibitor | |
| 650 | 4 | |a camzyos | |
| 650 | 4 | |a cardiomyopathy | |
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a clinical studies. | |
| 650 | 4 | |a mavacamten | |
| 650 | 4 | |a novel cardiac drug | |
| 700 | 1 | |a Shamim, Areeba |e verfasserin |4 aut | |
| 700 | 1 | |a Mirza, Sanoober |e verfasserin |4 aut | |
| 700 | 1 | |a Osama, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Naeem Muhammad, Iyad |e verfasserin |4 aut | |
| 700 | 1 | |a R Wei, Calvin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular & hematological agents in medicinal chemistry |d 2006 |g (2024) vom: 05. Apr. |w (DE-627)NLM161201482 |x 1875-6182 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0118715257283752240325082733 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 04 | ||